Floatz logo

Telmisartan

Hypertensive Disorder

The George InstituteSmall moleculePhase 4 / ApprovedDormant
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
81/ 100

Competitive context

33 Active assets in the Hypertensive Disorder cohort.

View all 50

Same molecule, other indications

Telmisartan is also rated in:

abdominal obesity-metabolic syndromeActive
BB
Indicative · Phase 4
70 / 100
View asset →
schizoaffective disorderDormant
BB
Indicative · Phase 4
68 / 100
View asset →
essential hypertensionActive
B
Indicative · Phase 4
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →